PACE研究:氟维司群、哌柏西利和阿维鲁单抗在CDK4/6抑制剂和芳香化酶抑制剂进展后的激素受体阳性/HER2阴性转移性乳腺癌中的随机II期研究
PACE是一项随机多中心II期试验,纳入220例既往CDK4/6抑制剂和芳香化酶抑制剂治疗后进展的激素受体阳性/HER2阴性转移性乳腺癌患者,按1:2:1随机接受氟维司群、氟维司群+哌柏西利或氟维司群+哌柏西利+阿维鲁单抗。氟维司群组与氟维司群+哌柏西利组的中位无进展生存期分别为4.8个月和4.6个月(HR 1.11,90%CI 0.79-1.55,P=0.62),差异无统计学意义。氟维司群+哌柏西利+阿维鲁单抗组的中位无进展生存期为8.1个月(对比氟维司群HR 0.75,90%CI 0.50-1.12,P=0.23)。
要点
- 在既往CDK4/6抑制剂和芳香化酶抑制剂进展后的HR+/HER2-转移性乳腺癌中,氟维司群联合哌柏西利对比氟维司群单药未改善无进展生存期。
- 氟维司群+哌柏西利+阿维鲁单抗组的中位无进展生存期为8.1个月,对比氟维司群的风险比为0.75(90%CI 0.50-1.12)。
- 基线存在ESR1和PIK3CA变异的患者中,氟维司群+哌柏西利和氟维司群+哌柏西利+阿维鲁单抗对比氟维司群的无进展生存期差异更大。
核心结论
- 在既往CDK4/6抑制剂联合芳香化酶抑制剂治疗进展的激素受体阳性/HER2阴性转移性乳腺癌患者中,氟维司群基础上加用哌柏西利对比氟维司群单药未改善无进展生存期。
- 加用阿维鲁单抗后观察到的无进展生存期延长值得在该患者人群中进一步研究。
研究设计与样本
- 随机多中心II期PACE试验纳入既往CDK4/6抑制剂和芳香化酶抑制剂治疗后进展的激素受体阳性/HER2阴性转移性乳腺癌患者。
- 患者按1:2:1随机分配至氟维司群(F)、氟维司群+哌柏西利(F+P)或氟维司群+哌柏西利+阿维鲁单抗(F+P+A)组。
- 主要终点为研究者评估的F组对比F+P组的无进展生存期。
- 2017年9月至2022年2月期间共随机分配220例患者,中位年龄57岁(范围25-83岁)。
- 大多数患者为绝经后(80.9%),40%初诊即为转移性乳腺癌,哌柏西利是最常见的既往CDK4/6抑制剂(90.9%)。
主要发现
- F组中位无进展生存期为4.8个月,F+P组为4.6个月(HR 1.11,90%CI 0.79-1.55,P=0.62)。
- F+P+A组中位无进展生存期为8.1个月(对比F组HR 0.75,90%CI 0.50-1.12,P=0.23)。
- 基线存在ESR1和PIK3CA变异的患者中,F+P和F+P+A对比F组的无进展生存期差异更大。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cyclin-dependent kinase (CDK) 4/6 inhibitors (CDK4/6is) are an important component of treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC), but it is not known if patients might derive benefit from continuation of CDK4/6i with endocrine therapy beyond initial tumor progression or if the addition of checkpoint inhibitor therapy has value in this setting. METHODS: The randomized multicenter phase II PACE trial enrolled patients with hormone receptor-positive/HER2- MBC whose disease had progressed on previous CDK4/6i and aromatase inhibitor (AI) therapy. Patients were randomly assigned 1:2:1 to receive fulvestrant (F), fulvestrant plus palbociclib (F + P), or fulvestrant plus palbociclib and avelumab (F + P + A). The primary end point was investigator-assessed progression-free survival (PFS) in patients treated with F versus F + P. RESULTS: Overall, 220 patients were randomly assigned between September 2017 and February 2022. The median age was 57 years (range, 25-83 years). Most patients were postmenopausal (80.9%), and 40% were originally diagnosed with de novo MBC. Palbociclib was the most common previous CDK4/6i (90.9%). The median PFS was 4.8 months on F and 4.6 months on F + P (hazard ratio [HR], 1.11 [90% CI, 0.79 to 1.55]; P = .62). The median PFS on F + P + A was 8.1 months (HR v F, 0.75 [90% CI, 0.50 to 1.12]; P = .23). The difference in PFS with F + P and F + P + A versus F was greater among patients with baseline ESR1 and PIK3CA alterations. CONCLUSION: The addition of palbociclib to fulvestrant did not improve PFS versus fulvestrant alone among patients with hormone receptor-positive/HER2- MBC whose disease had progressed on a previous CDK4/6i plus AI. The increased PFS seen with the addition of avelumab warrants further investigation in this patient population.
引用
- Mayer EL, Ren Y, Wagle N, et al. PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. J Clin Oncol. 2024. PMID: 38513188. doi:10.1200/JCO.23.01940
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。